<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134310">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353235</url>
  </required_header>
  <id_info>
    <org_study_id>steroids in COPD exacerbation</org_study_id>
    <nct_id>NCT01353235</nct_id>
  </id_info>
  <brief_title>Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Prospective Randomized Trial of Systemic Corticosteroids (Oral Prednisolone) in Severe Exacerbation of COPD Requiring Ventilatory Assistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Universitaire Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Universitaire Fattouma Bourguiba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of systematic administration of oral prednisolone (1mg/Kg/day) as an add on
      therapy in Chronic Obstructive Pulmonary Disease (COPD) patients admitted to intensive care
      unit (ICU) for severe exacerbation of COPD. Patients with pneumonia are excluded.

      Randomization is stratified according to ventilatory support: non invasive or conventional
      ventilation.The major outcome is the ICU mortality rate in overall population and stratified
      according to ventilatory mode (noninvasive ventilation (NIV) versus conventional).

      Secondary outcomes are superinfection necessitating a new antibiotic course, Length of
      mechanical ventilation (MV) (and ventilatory free days), Length of ICU stay, The frequency
      of gastric bleeding episodes that of frequency of hyperglycemic episodes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICU mortality rate</measure>
    <time_frame>ICU stay (on average patients will be followed 30 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of MV (and ventilatory free days)</measure>
    <time_frame>ICU stay (on average patients will be followed 30 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>usual care</intervention_name>
    <description>no drug administered</description>
    <arm_group_label>usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All COPD patients (according to the ATS definition) experiencing acute exacerbation
             originating in acute respiratory failure and requiring ICU admission will be included
             in the study.

        COPD exacerbation is defined by the increased frequency of cough, volume and purulence of
        sputum and that of wheeze.

        Acute respiratory failure is defined by the presence of hypercapnia with PaCO2 &gt;45mmHg
        associated with pH &gt; 7.35 and signs of respiratory muscle fatigue (contraction of
        accessory respiratory muscles, thoracoabdominal swinging ,..).

        Exclusion Criteria:

          -  Asthmatic patients defined by a reversible obstructive disease following nebulized
             bronchodilators,

          -  Patients with uncontrolled left heart failure,

          -  AECOPD patients with a radiologically documented pneumonia,

          -  Systemic corticotherapy within 30 days before screening,

          -  contra-indication to corticosteroids (active gastroduodenal ulcer, uncontrolled
             sepsis, etc. ..)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fekri Abroug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU F.Bourguiba Monastir</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fekri Abroug, MD</last_name>
    <phone>+21673460672</phone>
    <email>f.abroug@rns.tn</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU F.Bourguiba</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fekri Abroug, MD</last_name>
      <phone>+21673460672</phone>
      <email>f.abroug@rns.tn</email>
    </contact>
    <investigator>
      <last_name>Lamia Besbes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fahmi Dachraoui, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Islem Ouanes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <reference>
    <citation>Chang KC, Leung CC, Kong FY. Corticosteroid administration and treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010 Oct 13;304(14):1554; author reply 1554-6. doi: 10.1001/jama.2010.1438.</citation>
    <PMID>20940378</PMID>
  </reference>
  <reference>
    <citation>Gunen H, Mirici A, Meral M, Akgün M. Steroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulized and systemic forms comparable? Curr Opin Pulm Med. 2009 Mar;15(2):133-7. doi: 10.1097/MCP.0b013e32832185da. Review.</citation>
    <PMID>19532028</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <lastchanged_date>May 12, 2011</lastchanged_date>
  <firstreceived_date>May 10, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Health Ministery</name_title>
    <organization>CHU F.Bourguiba Monastir</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>acute respiratory failure</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>non invasive ventilation</keyword>
  <keyword>steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
